Table 3:

Characteristics of the 32 Patients Enrolled in the SERF Trial

Patients (n)	32
Age (years)	67± 9
Gender
Male	29 (91%)
Female	3 (9%)
Ischemic Cardiomyopathy	18 (56%)
Prior MI	72%
Prior CABG	36%
Nonischemic-Cardiomyopathy	14 (44%)
Idiopathic	8
Sarcoid	3
Lamin A/C	1
Lymphocytic CM	1
Late stage HCM	1
EF	37%
NYHA Class
Class I	29%
Class II	45%
Class III	26%
VT Subtype
Monomorphic (32)	100%
Storm (n=3)	9%
Incessant	0%
Prior VT Ablation
Endocardialy	100%
Epicardialy	27%
Endo- and Epicardialy	27%
Diabetes Mellitus
Chronic Renal Disease	22%
Peripheral Vascular Disease	25%
Prior stroke (CVA/TIA)	16%
COPD	22%
AF/AFL	28%

n = Number of subjects; MI = myocardial infarction; CABG = Coronary artery bypass grafting; A/C = arrhythmogenic cardiomyopathy; HCM = hypertrophic cardiomyopathy; EF = ejection fraction; NYHC = New York Heart Association; = ; CVA = cerebral vascular accident; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease; AF/AFL = atrial fibrillation or atrial flutter